m+Medelevator.RU
← Поиск публикаций
Cancer cell · 2026

Integrated clinicogenomic analysis reveals the evolution and metastatic tropisms of advanced colorectal cancer.

СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Manca Paolo, Walch Henry, Xu Jierui, Small Natalie, Kris Ayush, Seffar Evan, Richards Allison, Xue Tiffany, Price Adam, Donoghue Mark T A, Fong Christopher, Waters Michele, Jee Justin, Deshmukh Sachin Kumar, Sledge George W, Malla Midhun, Cercek Andrea, Saltz Leonard, Segal Neil H, Stadler Zsofia K, Nusrat Maliha, Foote Michael B, Desai Avni, Chalasani Sree, Rao Devika, Connell Louise, Do Richard K G, Ganesh Karuna, Weiser Martin R, Berger Michael F, Solit David B, Shia Jinru, Vakiani Efsevia, Garcia-Aguilar Julio, Schultz Nikolaus, Sanchez-Vega Francisco, Chatila Walid K, Yaeger Rona

Аннотация

We performed an integrated clinical and genomic analysis of over 7,000 consecutively sequenced colorectal cancer (CRC) samples to comprehensively characterize genetic drivers and metastatic tropisms of CRC. We find that genomic evolutionary changes, such as clonal mutations and oncogenic mutant allelic imbalance, selectively enhance the impact of recurrent oncogenic alterations. We identify the relative timing of organ-specific metastasis, showing sequential metastatic progression in microsatellite stable CRC with brain and adrenal metastases as late events; metastatic sites that cluster together, such as lung, bone, and brain metastases; and genomic events that enhance or decrease risk for each metastatic site, with WNT pathway activation as overall protective while RAS pathway activation increased risk for spread to all metastatic sites. Our data suggest that despite the heterogeneity in CRC, genomic evolution increases the impact of recurrent alterations, and integrating information about tumor primary location and genomics can be used to predict organ-specific metastasis risk.

Предметные рубрики MeSH

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты